Purpose of Review <p>This review examines the mechanistic pathways linking obesity and cardiovascular disease, with particular emphasis on recent advancements in pharmacologic therapies. It evaluates the cardiovascular effects of novel anti-obesity medications and their integration into current treatment paradigms. Additionally, these pharmacologic strategies are contextualized alongside lifestyle interventions and metabolic bariatric surgery.</p> Recent Findings <p>Incretin agonist therapies, including both glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have shown substantial efficacy in weight reduction and cardiometabolic improvement. Clinical trials have demonstrated that these agents not only reduce body weight by 10–20% but also significantly lower the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and stroke. These benefits have been observed in both patients with and without diabetes mellitus, and the cardiovascular protection extends beyond glycemic control. Tirzepatide, in particular, has shown superior efficacy compared to GLP-1 monotherapy in weight loss.</p> Summary <p>Pharmacologic therapy has become a central pillar in the management of obesity-related cardiovascular risk. The emergence of agents with proven efficacy in both weight reduction and cardiovascular outcome improvement marks a paradigm shift in treatment. These findings support early and sustained use of pharmacotherapy in high-risk individuals, highlighting a need for integrated, personalized care strategies in obesity management.</p>